|
|
|
|
|
|
|
11.12.25 - 04:06
|
Gen-X TS Wu initiates UMC leadership transition (Digitimes)
|
|
|
Following several executives' retirements at TSMC and the company's succession planning, United Microelectronics Corporation (UMC) has initiated a leadership transition plan. TS Wu, a Gen-X executive, is reportedly set to take over as president, but UMC's spokesperson has declined to comment on market rumors....
|
|
|
|
|
|
|
|
|
09.12.25 - 07:06
|
UMC licenses Imec SiPh tech, plans risk production in 2026-27 (Digitimes)
|
|
|
UMC announced on December 8, 2025, that it has signed a technology licensing agreement with Belgium-based Imec to acquire the Imec iSiPP300 silicon photonics (SiPh) process. This process supports co-packaged optics (CPO) compatibility, enabling UMC to launch a 12-inch SiPh platform targeting next-generation high-speed connectivity applications....
|
|
|
05.12.25 - 08:06
|
UMC expands US supply chain with 8-inch wafer MOU with Polar Semiconductor (Digitimes)
|
|
|
UMC has finalized plans to invest in the US semiconductor manufacturing sector by signing a memorandum of understanding (MOU) with American foundry Polar Semiconductor on December 4, 2025. The two companies will explore collaboration opportunities for 8-inch wafer production within the US, targeting growing demand from automotive, data center, consumer electronics, aerospace, and defense industries....
|
|
|
|
|
|
|
|
|
|
|
31.10.25 - 05:06
|
UMC and Samsung present advanced packaging trends at APDC 2025 (Digitimes)
|
|
|
STATS ChipPAC held the Advanced Packaging Developer Conference 2025 (APDC 2025) at Resorts World Sentosa Convention Center in Singapore to explore the future of semiconductor packaging. The forum invited experts from academia and industry, presenting many of STATS ChipPAC's blueprints for advanced packaging and testing technologies....
|
|
|
|
|
29.10.25 - 14:21
|
UMC Reports Third Quarter 2025 Results (Business Wire)
|
|
|
22nm business traction remains robust and well positioned for future growth
Third Quarter 2025 Overview1:
Revenue: NT$59.13 billion (US$1.94 billion)
Gross margin: 29.8%; Operating margin: 18.8%
Revenue from 22/28nm: 35%
Capacity utilization rate: 78%
Net income attributable to shareholders of the parent: NT$14.98 billion (US$492 million)
Earnings per share: NT$1.20; earnings per ADS: US$0.197
TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC” or “The Company”), a leading global semiconductor foundry, today announced its consolidated operating results for the third quarter of 2025.
Third quarter consolidated revenue was NT$59.13 billion, increasing 0.6% from NT$58.76 billion in 2Q25. Compared to a year ago, 3Q25 revenue decreased 2.2%. Consolidated gross margin for 3Q25 was 29.8%. Net income attributable to the shareholders of the parent was NT$14.98 billion, with earnings per ordinary share of NT$1.20.
Jason Wang, co-president of UMC, said, “In t...
|
|
|
|
|
|
|
|
|
10.10.25 - 13:09
|
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire)
|
|
|
Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical SystemHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical study results from the nPulse™ Cardiac Surgical System first-in-human feasibility study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark.
The feasibility study is intended to assess the initial safety and efficacy of the nPulse Cardiac Surgical System for the treatment of Atrial Fibrillation (NCT06355063). To date, 44 patients have been treated by investigators in Europe, including Dr. Bart van Putte in cases performed at St. Antonius Hospital Nieuwegein, Netherlands, Dr. Bart Maesen performing cases at Maastricht UMC+, Maastricht, Netherlands, and Dr. Antoine Driessen performing cases at A...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
